A total of 268 eligible patients with HER2‐positive solid tumors were included, such as those with locally advanced, unresectable, or metastatic biliary tract, bladder, cervical, endometrial, ovarian, pancreatic, and salivary gland cancer, as well as other solid cancers like malignant neoplasm of unknown primary site, extramammary Paget disease, oropharyngeal neoplasm, cutaneous melanoma, and various others. This evidence concerns the gene ERBB2 and cancer.